HOME >> MEDICINE >> NEWS
UCLA studies experimental cancer drug

Men with high-risk prostate cancer who are candidates for surgery are being sought to test a molecularly targeted experimental drug that may interrupt the signal that is driving their cancer and keep the disease from recurring.

The early-phase clinical trial is based on basic research discoveries made in Jonsson Cancer Center laboratories. UCLA researchers have successfully tested the drug in laboratory and animal models. They hope to translate that benefit into patients in the clinic, said Dr. Charles Sawyers, co-principal investigator for the study and the Jonsson Cancer Center scientist whose basic research resulted in the clinical trial.

UCLA laboratory studies have shown that some patients with prostate cancer have lost PTEN, a tumor-suppressor gene. In some patients who have lost PTEN, a gene called mTOR located downstream in the cell-signaling pathway gets turned on and may be driving the cancer. Sawyers, along with co-principal investigator Dr. Robert Reiter, will test a drug called CCI779, which they believe targets mTOR.

"We discovered that tumors missing PTEN seem to be very responsive to CCI779, and it's very clear at a molecular biology level why," Sawyers said. "When you've lost PTEN, mTOR activity gets turned up and tumors become dependent on it for their growth. So a drug that inhibits mTOR should impact the tumor cells but have no effect on the normal cells."

Armed with his laboratory discoveries, Sawyers proposed the prostate cancer study to Wyeth Pharmaceuticals, and the clinical trial was designed. UCLA's Jonsson Cancer Center is the only West Coast site offering this study. Other sites participating include MD Anderson Cancer Center in Texas and Fox Chase Cancer Center in Philadelphia, Sawyers said.

Because CCI779 targets only what is broken in the cancer cell, it is expected to cause very few side effects, Sawyers said.

UCLA researchers are seeking study volunteers with newly diagnosed prostate ca
'"/>

Contact: Kim Irwin
kirwin@mednet.ucla.edu
310-206-2805
University of California - Los Angeles
4-Dec-2003


Page: 1 2

Related medicine news :

1. New studies suggest airborne SARS transmission is possible
2. New studies show mixed results on epilepsy drugs and birth defects
3. Brain imaging studies investigate pain reduction by hypnosis
4. Impact of scientific advances on drug studies and membrane research to be explored
5. Two studies find evidence that sunlight may have beneficial influence on cancer
6. More studies on risks and benefits of COX-2 inhibitors published in Archives of Internal Medicine
7. Animal studies show stem cells might make biological pacemaker
8. Infants, children prefer sounds over pictures and only slowly become visually oriented, studies find
9. New studies on Ritalin and Alzheimers Disease highlight ACNP Annual Meeting
10. Gender and sex hormones affect the brains pain response and more, according to new studies
11. Analysis of tamoxifen studies reveals slight increase of stroke risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UCLA studies experimental cancer drug

(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... 2014 stronger than ever, having invested more than ... injured service members, veterans and their families. , ... for nearly a dozen nonprofits, helping with: veteran ... nursing scholarships; and life-coaches for severely injured veterans. ...
(Date:12/22/2014)... 22, 2014 Explorys, the leader in ... its leadership team: Greg Yarrington as Vice President of ... Patrick Wells as Vice President of Solutions. These new ... new jobs in 2015 to support client demand for ... platform-as-a-service offerings, and growth of its partner network. ...
(Date:12/22/2014)... 22, 2014 Give a loved one ... gift of health and vitality. , For a limited ... top-selling anti-aging formulas in special Holiday Wellness gift packages ... , Each bottle contains cutting-edge, proven nutritional support ... work as well as we age. , ...
(Date:12/22/2014)... 2014 The MedTech industry is gearing up ... owned subsidiary of PartnerTech AB of Sweden, is prepared to ... additional ISO Certification. , All signs point to growth in ... likelihood of a repeal of the excise tax originally levied ... is anticipating annual growth of 9.3% and PartnerTech Inc. is ...
(Date:12/22/2014)... New York NY (PRWEB) December 22, 2014 ... reports that a federal panel of judges has granted ... lawsuits in the U.S. District Court, Eastern District ... (JPML) issued an order on December 12 to transfer ... actions–pending in 22 districts to the Louisiana court for ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 2Health News:Explorys Continues to Experience Rapid Growth, Adds Three Healthcare IT Executives to Its Leadership Team 3Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... Research and Markets ( http://www.researchandmarkets.com/research/hmlfbq/investment ... "Investment Analysis of the US Medical Device Sector ... http://photos.prnewswire.com/prnh/20130307/600769 This ... sector identifies the key trends and rationale for ... mergers and acquisitions. The study will ...
(Date:12/22/2014)... , Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation ... focused on discovering, developing and commercializing innovative therapies ... today issued the following open letter to shareholders ... Dr. Med. Sc. Dear RXi Shareholders, ... number of inaccurate statements posted on certain social ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3Investment Analysis of the US Medical Device Sector 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
Cached News: